Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors

被引：4

作者：

Kartolo, Adi ^{[1
]}

Yeung, Cynthia ^{[2
]}

Hopman, Wilma ^{[3
]}

Fung, Andrea S. ^{[1
]}

Baetz, Tara ^{[1
]}

Badillo, Francisco E. Vera ^{[1
]}

机构：

[1] Queens Univ, Canc Ctr Southeastern Ontario, Dept Oncol, Kingston, ON K7L 3N6, Canada

[2] Queens Univ, Kingston Hlth Sci Ctr, Dept Med, Kingston, ON K7L 3N6, Canada

[3] Queens Univ, Kingston Hlth Sci Ctr, Dept Publ Hlth Sci, Kingston, ON K7L 3N6, Canada

来源：

IMMUNOTHERAPY | 2022年 / 14卷 / 10期

关键词：

complete response; immune checkpoint inhibitors; overall survival; predictive factors; prognostic factors; 5-YEAR SURVIVAL; PLUS AXITINIB; PEMBROLIZUMAB; SUNITINIB; NIVOLUMAB; SURROGATE; EFFICACY; MELANOMA;

D O I：

10.2217/imt-2021-0220

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To evaluate overall survival in advanced cancer patients who achieved complete response (CR) with immune checkpoint inhibitor (ICI) therapy. Methods: This retrospective study included patients with advanced unresectable or metastatic cancer who received at least one cycle of palliative-intent ICI. Best overall response was used to define response groups. Results: 21 (7%) of 322 patients achieved CR. Multivariate analysis demonstrated that CR was independently associated with better overall survival compared with disease progression (hazard ratio: 0.012; 95% CI: 0.002-0.090) and stable disease (hazard ratio: 0.063; 95% CI: 0.009-0.464) as well as a nonsignificant trend toward better overall survival compared with partial response (hazard ratio: 0.169; 95% CI: 0.023-1.252) regardless of cancer type, ICI regimen or ICI line. Conclusion: Patients who achieved CR had longer survival compared with patients who did not achieve CR.

引用

页码：777 / 787

页数：11

共 26 条

[1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial [J].

Albiges, Laurence ;

Tannir, Nizar M. ;

Burotto, Mauricio ;

McDermott, David ;

Plimack, Elizabeth R. ;

Barthelemy, Philippe ;

Porta, Camillo ;

Powles, Thomas ;

Donskov, Frede ;

George, Saby ;

Kollmannsberger, Christian K. ;

Gurney, Howard ;

Grimm, Marc-Oliver ;

Tomita, Yoshihiko ;

Castellano, Daniel ;

Rini, Brian, I ;

Choueiri, Toni K. ;

Saggi, Shruti Shally ;

McHenry, M. Brent ;

Motzer, Robert J. .

ESMO OPEN, 2020, 5 (06)

[2] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[3]

Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]

[4]

ClinicalTrials.gov, 2022, DUR ANT PD 1 MET MEL

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation [J].

Gauci, Marie-Lea ;

Lanoy, Emilie ;

Champiat, Stephane ;

Caramella, Caroline ;

Ammari, Samy ;

Aspeslagh, Sandrine ;

Varga, Andrea ;

Baldini, Capucine ;

Bahleda, Rastilav ;

Gazzah, Anas ;

Michot, Jean-Marie ;

Postel-Vinay, Sophie ;

Angevin, Eric ;

Ribrag, Vincent ;

Hollebecque, Antoine ;

Soria, Jean-Charles ;

Robert, Caroline ;

Massard, Christophe ;

Marabelle, Aurelien .

CLINICAL CANCER RESEARCH, 2019, 25 (03) :946-956

[8] Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 [J].

Hamid, O. ;

Robert, C. ;

Daud, A. ;

Hodi, F. S. ;

Hwu, W. J. ;

Kefford, R. ;

Wolchok, J. D. ;

Hersey, P. ;

Joseph, R. ;

Weber, J. S. ;

Dronca, R. ;

Mitchell, T. C. ;

Patnaik, A. ;

Zarour, H. M. ;

Joshua, A. M. ;

Zhao, Q. ;

Jensen, E. ;

Ahsan, S. ;

Ibrahim, N. ;

Ribas, A. .

ANNALS OF ONCOLOGY, 2019, 30 (04) :582-588

[9] Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis [J].

Huang, Min ;

O'Shaughnessy, Joyce ;

Zhao, Jing ;

Haiderali, Amin ;

Cortes, Javier ;

Ramsey, Scott D. ;

Briggs, Andrew ;

Hu, Peter ;

Karantza, Vassiliki ;

Aktan, Gursel ;

Qi, Cynthia Z. ;

Gu, Chenyang ;

Xie, Jipan ;

Yuan, Muhan ;

Cook, John ;

Untch, Michael ;

Schmid, Peter ;

Fasching, Peter A. .

CANCER RESEARCH, 2020, 80 (24) :5427-5434

[10] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J-J ;

Rutkowski, P. ;

Lao, C. D. ;

Cowey, C. L. ;

Schadendorf, D. ;

Wagstaff, J. ;

Dummer, R. ;

Ferrucci, P. F. ;

Smylie, M. ;

Hogg, D. ;

Hill, A. ;

Marquez-Rodas, I. ;

Haanen, J. ;

Guidoboni, M. ;

Maio, M. ;

Schoffski, P. ;

Carlino, M. S. ;

Lebbe, C. ;

McArthur, G. ;

Ascierto, P. A. ;

Daniels, G. A. ;

Long, G. V. ;

Bastholt, L. ;

Rizzo, J. I. ;

Balogh, A. ;

Moshyk, A. ;

Hodi, F. S. ;

Wolchok, J. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546

← 1 2 3 →